Gastrointestinal Stromal Tumors: Innovation from Diagnosis to Treatment Based on 15 Years of Experience of a Peripheral Hospital in Portugal
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2017, Vol 3, Issue 1
Abstract
Aim: To investigate fifteen years of experience, in managing GISTs, according to best clinical practice, on a peripheral Portuguese Hospital. Define the behavior of GIST’s and the association between the histological, immunehistochemistry characteristics and disease progression. Question if the optimal treatment was delivered in GIST patients, based on medical evidence, where limitations on evaluating molecular signatures exists. Methods: A retrospective analysis of cases treated in Hospital of Entre Douro and Vouga from 1 January 1999 to 31 December 2014 was performed. Demographic characteristics were evaluated related to tumor characteristics according to the National Institute of Health criteria and disease progression. All patients were evaluated in a multidisciplinary team. An expert treatment decision was made according to the National Institute of Health criteria of Gastrointestinal stromal tumor’s risk of recurrence after surgery. Statistical study was performed using SPSS version. Results: Sixty-three cases were evaluated, 61.9% in female patients and 38.1% male. The median age at diagnosis was 69 years. A progressive increase in the incidence of GISTs was documented since 1999 to 2014. The most common source locations was the stomach with forty-five patients (71.4%), When assessing the Mitotic count, 27% was superior to 5 mitosis/50HPF and 73% was inferior to 5 mitosis /50HPF. Sixty-two patients underwent surgery with R0 resection rate of 94% Immunohistochemistry was performed in all patients, and sixty-one patients were positive for CD117. Only two patients were CD117 negative. No KIT gene mutation analysis was performed. Regarding the biological risk of recurrence or metastasis, according to the National Institute of Health, 25,4 % of the patients had a very high risk, 19,0% had an intermediate risk, 34,9% had a low risk and 20,6 % had a very low risk. Of the 63 patients, 25.4% (n=16) were submitted to adjuvant treatment with imatinib (400 mg/ daily) during 3 years. Only 7.9% (n=5) received palliative treatment with imatinib and sunitinib. Only in 11% of the patients the disease progressed (median time to progression of 36 months). The mortality rate was 12.7% (n=8). Fifty-five patients were alive (87.3%) at the end of this retrospective study. Conclusions: Mutation analysis was not performed, which might have influenced the treatment and prognosis. Optimize therapy based on molecular signatures are extremely important for a cost-effective treatment.
Authors and Affiliations
Joana Espiga de Macedo
Keywords
Related Articles
- EP ID EP551964
- DOI 10.17140/CSMMOJ-3-115
- Views 125
- Downloads 0
Neurofibromatosis Type I and Multiple Gastrointestinal Stromal Tumors: A Unique Identity
Von Recklinghausen’s disease (VRD) is a genetic disorder characterized by the growth of multiple noncancerous tumors of nerves and skin (neurofibromas) and areas of hypo or hyperpigmentation of the skin. It is also known...
Flavones and Flavonols may have Clinical Potential as CK2 Inhibitors in Cancer Therapy
The serine-threonine kinase CK2, which targets over 300 cellular proteins, is over expressed in all cancers, presumably reflecting its ability to promote proliferation, spread, and survival through a wide range of comple...
Treatment of Stage I Seminoma
Stage I testicular seminoma is a curable condition. The primary treatment is high inguinal orchiectomy. The treatment options after surgery includes radiotherapy, chemotherapy with single agent carboplatin and active sur...
Rounding Down Chemotherapeutic Agents to the Nearest Vial Size as a Cost Containment Measure
Background: High cancer treatment costs significantly affect health care expenditures. Drug waste reduction of costly drugs can reduce the treatment cost. Methods: A retrospective study conducted at King Abdulaziz Medica...
The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy
Early life exposure to a variety of insults during sensitive windows of development can reprogram normal physiological responses and alter disease susceptibility later in life. During this process, inflammation triggered...